Lazard Asset Management
AVDL

Lazard Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Lazard Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,166
Closed -$111K – 2298
2023
Q1 		$111K Sell
12,166
-36,930
-75% -$304K ﹤0.01% 1493
2022
Q4 		$351K Sell
49,096
-95,861
-66% -$672K ﹤0.01% 1185
2022
Q3 		$726K Buy
144,957
+2,380
+2% +$13.1K ﹤0.01% 1038
2022
Q2 		$347K Sell
142,577
-3,565
-2% -$14.6K ﹤0.01% 1174
2022
Q1 		$998K Sell
146,142
-11,495
-7% -$79K ﹤0.01% 998
2021
Q4 		$1.27M Buy
157,637
+98,965
+169% +$905K ﹤0.01% 977
2021
Q3 		$574K Buy
58,672
+23,702
+68% +$187K ﹤0.01% 1151
2021
Q2 		$235K Hold
34,970
– – ﹤0.01% 1199
2021
Q1 		$316K Buy
34,970
+5,110
+17% +$41.3K ﹤0.01% 1046
2020
Q4 		$199K Buy
+29,860
New +$187K ﹤0.01% 1099
2018
Q2 		– Sell
-600
Closed -$4K – 1031
2018
Q1 		$4K Hold
600
– – ﹤0.01% 1001
2017
Q4 		$4K Buy
600
+200
+50% +$1.88K ﹤0.01% 1020
2017
Q3 		$4K Buy
+400
New +$3.82K ﹤0.01% 935
2015
Q1 		– Sell
-1,040
Closed -$17K – 1120
2014
Q4 		$17K Hold
1,040
– – ﹤0.01% 1051
2014
Q3 		$14K Buy
+1,040
New +$14.9K ﹤0.01% 965

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Lazard Asset Management's AVDL Position: Q2 2023 in Review

Lazard Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2023, closing a stake of 12,166 shares — an estimated $111K sold.

Lazard Asset Management first reported a position in AVDL in Q3 2014 and held it in 15 quarters. The position peaked at $1.27M in Q4 2021. 101 funds tracked by Wall St. Rank hold AVDL as of Q2 2023.

  • Lazard Asset Management reported no remaining Avadel Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Lazard Asset Management sold 12,166 Avadel Pharmaceuticals shares in Q2 2023, an estimated $111K.
  • Lazard Asset Management first reported a position in Avadel Pharmaceuticals in Q3 2014 and held it in 15 quarters.
  • Lazard Asset Management's Avadel Pharmaceuticals position peaked at $1.27M in Q4 2021.
  • 101 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2023.

Based on Lazard Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.